Methylated CD155 protein and its applications

By methylating arginine at position 109 of the CD155 protein and utilizing the PRMT6 and JMJD6 enzymes to regulate the CD155/TIGIT axis, JMJD6 inhibitors or PRMT6 activators were developed. This solved the problem of unsatisfactory efficacy of immune checkpoint inhibitors in TNBC, enhanced the anti-tumor immune response of CD8+ T cells, and provided a new treatment strategy.

CN123106877APending Publication Date: 2026-11-17PUTIAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611484721.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-22
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Current immune checkpoint inhibitors for the treatment of triple-negative breast cancer are not effective, exhibit immune escape mechanisms, and lack highly effective and low-toxicity targeted therapy strategies.

Method used

By methylating arginine at position 109 of the CD155 protein, reversible methylation and demethylation can be performed using PRMT6 and JMJD6 enzymes to dynamically regulate the activity of the CD155/TIGIT axis, and to develop JMJD6 inhibitors such as SKLB325 or PRMT6 activators as therapeutic agents.

Benefits of technology

It significantly enhanced the anti-tumor immune response of CD8+ T cells, inhibited the progression of TNBC, provided a new immunotherapy strategy, and was effective for patients resistant to existing antibody drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106877A_ABST
    Figure CN123106877A_ABST
Patent Text Reader

Abstract

This invention discloses a methylated CD155 protein and its applications. The methylated CD155 protein has an amino acid sequence as shown in SEQ ID NO:1 or an amino acid sequence with at least 70% sequence identity and does not significantly alter the ability to inhibit the binding of CD155 to TIGIT. Specifically, position 109 of the CD155 protein is a methylated arginine residue. This invention not only discloses and verifies for the first time that CD155 methylation can affect binding to TIGIT, but also systematically identifies key writers (PRMT6) and erasers (JMJD6), forming a complete molecular loop. Furthermore, this invention proposes for the first time novel druggable targets (JMJD6, PRMT6), providing a novel TNBC immunotherapy strategy and offering new hope for patients resistant to existing antibody drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biotechnology, specifically to methylated CD155 protein and its applications. Background Technology

[0002] Triple-negative breast cancer (TNBC) is a malignant tumor lacking expression of estrogen receptor (ER), progesterone receptor (PR), and HER2 receptor, accounting for 15%-20% of breast cancers. TNBC typically presents with high malignancy, a high risk of early recurrence and metastasis, and generally poor prognosis. Currently, chemotherapy remains the cornerstone of its systemic treatment, but its efficacy has plateaued, and it has significant toxic side effects. Therefore, exploring and developing new, highly effective, and low-toxicity targeted therapies for TNBC has become an urgent clinical challenge. In recent years, immune checkpoint inhibitors (ICIs), represented by PD-1 / PD-1L inhibitors, have made groundbreaking progress in cancer treatment. By blocking tumor immune escape pathways and activating the body's specific anti-tumor immune response, they have demonstrated excellent efficacy in various malignant tumors. However, in TNBC, the overall response rate of ICIs remains unsatisfactory, strongly suggesting the existence of other dominant immune escape mechanisms in TNBC. Therefore, systematically identifying novel immune checkpoint molecules in TNBC, elucidating their functional regulatory mechanisms, and developing corresponding targeted intervention strategies have become the core challenge and key pathway to improving the efficacy of TNBC immunotherapy. Summary of the Invention

[0003] In view of the deficiencies in the prior art, the present invention provides the following technical solution:

[0004] In a first aspect, the present invention provides a methylated CD155 protein having an amino acid sequence as shown in SEQ ID NO:1 or an amino acid sequence having at least 70% sequence identity and without significantly altering the ability to inhibit the binding of CD155 to TIGIT, wherein the 109th position of the CD155 protein is a methylated arginine.

[0005] In the present invention, SEQ ID The sequence of NO:1 is: MARAMAAAWPLLLVALLVLSWPPPTGDVVVQAPTQVPGFLGDSVTLPCYLQVPNMEVTHVSQLTWARHGESGSMAVFHQTQGPSYSESKRLEFVAA RLGAELRNASLRMFGLRVEDEGNYTCLFVTFPQGSRSVDIWLRVLAKPQNTAEVQKVQLTGEPVPMARCVSTGGRPPAQITWHSDLGGMPNTSQVPGFLSGTVTVTS LWILVPSSQVDGKNVTCKVEHESFEKPQLLTVNLTVYYPPEVSISGYDNNWYLGQNEATLTCDARSNPEPTGYNWSTTMGPLPPFAVAQGAQLLIRPVDKPINTTLI CNVTNALGARQAELTVQVKEGPPSEHSGISRNAIIFLVLGILVFLILLGIGIYFYWSKCSREVLWHCHLCPSSTEHASASANGHVSYSAVSRENSSSQDPQTEGTR.

[0006] In this invention, "no significant change" means that it is not statistically significant.

[0007] In a second aspect, the present invention provides the use of at least one of the following (a1)-(a3) in the development, screening, or preparation of medicaments for the prevention and / or treatment and / or prognosis of triple-negative breast cancer:

[0008] (a1) The methylated CD155 protein according to claim 1 is used as a target;

[0009] (a2) PRMT6, which catalyzes CD155 protein methylation modification, was used as a target;

[0010] (a3) JMJD6, which is a demethylated CD155 protein, was used as the target.

[0011] The research of this invention reveals that PRMT6 and JMJD6, a pair of enzymes with opposite functions, dynamically regulate the activity of the CD155 / TIGIT axis by reversibly modifying and demethylating the R109 site of CD155, thereby playing a key role as both "brake" and "accelerator" in the TNBC immune microenvironment.

[0012] In the present invention, the sequence of PRMT6 is as follows SEQ ID NO 2 shown: MSQPKKRKLESGGGGEGGEGTEEEDGAEREAALERPRRTKRERDQLYYECYSDVSVHEEMIADRVRTDAYRLGILRNWAALRGKTVLDVGAGTGILSIFCAQAGARRVYAVEASAIWQQAREVVRFNGLEDRVHVLPGPVETVELPEQVDAIVSEWMGYGLLHESMLSSVLHARTKWLKEGGLLLP ASAELFIAPISDQMLEWRLGFWSQVKQHYGVDMSCLEGFATRCLMGHSEIVVQGLSGEDVLARPQRFAQLELSRAGLEQELEAGVGGRFRCSCYGSAPMHGFAIWFQVTTFPGGESEKPLVLSTSPFHPATHWKQALLYLNEPVQVEQDTDVSGEITLLPSRDNPRRLRVLLRYKVGDQEEKTKDFAMED.

[0013] In this invention, the sequence of JMJD6 is as shown in SEQ ID NO 3 below: MNHKSKKRIREAKRSARPELKDSLDWTRHNYYESFSLSPAAVADNVERADALQLSVEEFVERYERPYKPVVLLNAQEGWSAQEKWTLERLKRKYRNQKFKCGEDNDGYSVKMKMKYYIEYMESTRDDSPLYIFDSSYGEHPKRRKLLEDYKVPKFFTDDLFQYAGEKRRPPYRWFVMGPPRSGTGIHIDPLGTSAWNALV QGHKRWCLFPTSTPRELIKVTRDEGGNQQDEAITWFNVIYPRTQLPTWPPEFKPLEILQKPGETVFVPGGWWHVVLNLDTTIAITQNFASSTNFPVVWHKTVRGRPKLSRKWYRILKQEHPELAVLADSVDLQESTGIASDSSSDSSSSSSSSDSDSECESGSEGDGTVHRRKKRRTCSMVGNGDTTSQDDCVSKERSSSR.

[0014] Thirdly, the present invention provides a biomaterial comprising at least one of the following (b1)-(b4):

[0015] (b1) A nucleotide sequence expressing the methylated CD155 protein described above, or a nucleotide sequence having at least 70% sequence identity with the nucleotide sequence described above, and without significantly altering the ability to inhibit the binding of CD155 to TIGIT.

[0016] (b2) An expression cassette comprising the nucleotide sequence described in (b1);

[0017] (b3) A recombinant vector comprising the nucleotide sequence described in (b1) or the expression cassette described in (b2);

[0018] (b4) A recombinant host cell comprising the nucleotide sequence of (b1) or the expression cassette of (b2) or the recombinant vector of (b3).

[0019] In this invention, unless otherwise stated, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Furthermore, to better understand this invention, definitions and explanations of relevant terms are provided below.

[0020] In this invention, the term "vector" generally refers to a vector capable of delivering exogenous DNA or a target gene into a host cell for amplification and / or expression. Those skilled in the art can select a suitable vector based on the purpose of genetic engineering and the properties of the recipient cell. The vectors include, but are not limited to: plasmids, phages (such as λ phage or M13 phage), cosmids (i.e., Cosmids), phagemids, shuttle vectors (such as yeast expression vectors), Ti plasmids, artificial chromosomes (such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC), P1 artificial chromosomes (PAC), or Ti plasmid artificial chromosomes (TAC)), viral vectors (such as baculovirus vectors, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, poxviruses, papillomaviruses, papillomaviruses (such as SV40), and herpesviruses (such as herpes simplex virus).

[0021] In this invention, the term "host cell (also called recipient cell)" generally refers to any type of cell that can be used to introduce the vector. The host cell can be a eukaryotic cell (e.g., plant cell, animal cell, fungus, or algae) or a prokaryotic cell (e.g., bacteria or protozoa). The term "host cell" is understood to refer not only to the specific recipient cell but also to its offspring, which, due to natural, accidental, or intentional mutations and / or alterations, need not be completely identical to the original parent cell but are still included within the scope of the host cell.

[0022] In this invention, the term "endogenous" generally refers to any substance that originates from or is produced within a living organism, cell, tissue, or system.

[0023] In this invention, the term "exogenous" generally refers to any substance introduced from or generated outside of a living organism, cell, tissue, or system.

[0024] Fourthly, the present invention provides the use of a substance that inhibits the binding of CD155 to TIGIT in the development, screening, or preparation of medicaments for the prevention and / or treatment of triple-negative breast cancer, characterized in that the substance that inhibits the binding of CD155 to TIGIT comprises at least one of the following (c1)-(c4):

[0025] (c1) The methylated CD155 protein according to claim 1;

[0026] (c2) The biomaterial according to claim 3;

[0027] (c3) PRMT6 activator;

[0028] (c4) JMJD6 inhibitor.

[0029] In this invention, "inhibitor (also known as antagonist)" has the meaning known in the art and can refer to any substance that reduces (downregulates) the level and / or activity of a target protein or gene. The inhibitor can also be defined as any substance that inhibits cytokines, receptors, signaling pathways, etc.

[0030] In this invention, "activator" has a meaning known in the art and can refer to any substance that increases (upregulates) the level and / or activity of a target protein or gene. The activator can also be defined as any substance that activates cytokines, receptors, signaling pathways, etc.

[0031] In this invention, the "JMJD6 inhibitor" can be a substance that inhibits the replication, transcription, translation, post-transcriptional modification, and / or post-translational modification of the JMJD6 gene, or a substance that inhibits or reduces the content, activity, and / or function of the JMJD6 protein. The JMJD6 inhibitor includes substances that cause the JMJD6 gene to be deleted or inactivated through techniques such as gene knockdown, gene editing, and gene knockout. The JMJD6 inhibitor also includes substances that can target and bind to the JMJD6 protein, inhibit the activity of the JMJD6 protein, or prevent the JMJD6 protein from performing its function. The substances may include, but are not limited to, nucleic acid molecules, carbohydrates, lipids, small molecule compounds, antibodies, peptides, proteins, recombinant vectors (such as gene editing vectors), recombinant cells, and viral vectors (such as lentiviruses and adeno-associated viruses). The nucleic acid molecule can be a nucleic acid molecule specifically targeting JMJD6 used in RNA interference technology, such as double-stranded RNA (dsRNA), small interfering RNA (siRNA), microRNA (miRNA), and short hairpin RNA (shRNA). The nucleic acid molecule can also be antisense RNA (asRNA) and antisense oligonucleotides (AON) used in antisense nucleic acid technology. The nucleic acid molecule also includes aptamers and ribozymes. The antibody can include monoclonal antibodies, polyclonal antibodies, bispecific antibodies, Fab antibodies, Fv antibodies, single-chain antibodies (ScFv), single-domain antibodies, and minimal recognition units (MRUs). Preferably, the forward sequence of the shRNA is shown in SEQ ID NO 4: 5'-CGGUGCAAGUGGAGCAAGA-3', and the reverse sequence of the shRNA is shown in SEQ ID NO 5: 5'-UCUUGCUCCACUUGCACCG-3'. In this invention, the term "gene knockdown" also refers to the technique of inactivating or silencing gene expression at the post-transcriptional or translational level without altering the gene's DNA sequence. Gene knockdown includes techniques such as RNA interference, Morpholino interference, antisense nucleic acid techniques, and ribozyme techniques.

[0032] In this invention, the term "gene editing" generally refers to the ability to alter a specific gene sequence within any cell, including somatic cells, resulting in base deletions, duplications, insertions, frameshift mutations, and replacements or knockouts of target genes. This allows for the substitution, deletion, splicing, and single-base alterations of the genome sequence—essentially, the technology to arbitrarily "edit" the genome or the sequence of a specific gene. Gene editing includes zinc finger ribozyme gene knockout technology, TALEN gene editing technology, and more.

[0033] In this invention, the term "gene knockout" generally refers to a technique that uses an exogenous mutated gene to replace an endogenous normal homologous gene through homologous recombination, thereby inactivating the endogenous gene. This includes complete gene knockout (e.g., complete mutation of the target gene based on a substitution-type or insertion-type targeting vector) and conditional gene knockout (e.g., tissue-specific knockout based on the Cre_LoxP recombinase system or the FLP_FRT recombinase system).

[0034] In this invention, the term "RNA interference (RNAi)" generally refers to a technique that uses double-stranded RNA (dsRNA) to induce the degradation of mRNA of a target gene homologously complementary to it, thereby silencing gene expression and inducing post-transcriptional gene silencing (PTGS) to prevent gene expression. Double-stranded RNA (dsRNA) is the trigger for RNAi, inducing the degradation of its complementary single-stranded RNA (ssRNA). Long dsRNA can be cleaved into small dsRNA fragments, i.e., small interfering RNA (siRNA), by the Dicer enzyme in the cell, and siRNA mediates mRNA cleavage. Therefore, RNAi can also be achieved by introducing siRNA corresponding to the target gene. Furthermore, a gene encoding RNA with inverted repeat sequences that can form hairpins (i.e., short hairpin RNA, shRNA) can be introduced. This gene continuously provides dsRNA in the form of a hairpin structure, allowing RNAi to continue. RNA interference in a broader sense also includes transcriptional gene silencing (pretranscriptional gene silencing) induced in gene regulatory regions. This silencing process involves DNA methylation rather than mRNA degradation. The siRNA used to silence genes acts directly on the regulatory regions of the gene, not the coding regions. RNA interference can also include translational gene silencing (translational silencing). For example, microRNAs (miRNAs, a type of single-stranded RNA molecule) primarily silence gene expression by preventing mRNA translation and interfering with the accumulation of the target mRNA protein product.

[0035] In this invention, the term "Morpholino interference technology" generally refers to replacing the five-carbon sugar ring on a traditional nucleotide with morpholino, and altering the original phosphate group, so that the molecule as a whole is free of any charge, cannot be recognized and degraded by RNase and DNase, and is extremely stable. Its principle is the same as antisense nucleic acid technology; it binds to the mRNA molecule through complementarity with the homologous sequence of the target gene mRNA, thereby preventing the binding of other molecules and proteins to the specific mRNA nucleic acid sequence, ultimately preventing the target gene mRNA from being translated into protein.

[0036] In this invention, the term "antisense nucleic acid technology" generally refers to the technology that utilizes the principle that antisense RNA can bind complementary to specific mRNA molecules with homologous sequences, thereby inhibiting the processing and translation of that mRNA. This involves artificially synthesizing antisense RNA or introducing its gene into cells to suppress the expression of specific genes. Antisense nucleic acid technology mainly includes antisense RNA (asRNA) and antisense oligonucleotides (AON).

[0037] In this invention, the term "ribozyme technology" generally refers to the technique of using ribozymes to cleave and degrade target RNA molecules. Ribozymes are a class of RNA molecules with biocatalytic activity that can specifically bind to and cleave target RNA molecules, thereby achieving the degradation of specific RNA molecules and inhibiting the expression of target genes. Ribozymes include hammerhead ribozymes, hairpin ribozymes, hepatitis D virus ribozymes, VS (Varkud satellite) ribozymes, and class I intron ribozymes, etc.

[0038] Fifthly, the present invention provides the use of genes and / or proteins in the methylation and demethylation pathway of the CD155 protein at position 109 described above in the preparation, development, screening, or preparation of medicaments for the prevention and / or treatment of triple-negative breast cancer.

[0039] Furthermore, the genes and / or proteins in the pathway include at least one of the following (d1)-(d2):

[0040] (d1) PRMT6 gene or protein;

[0041] (d2) JMJD6 gene or protein;

[0042] The PRMT6 gene or protein can promote methylation modification, and the JMJD6 gene or protein can demethylate modification, thereby reversibly methylating and demethylating position 109 of CD155 in the pathway.

[0043] In a sixth aspect, the present invention provides a pharmaceutical composition for treating triple-negative breast cancer, comprising:

[0044] Therapeutic effective amounts of active ingredients; and

[0045] Pharmaceutical carriers or pharmaceutical excipients

[0046] The active ingredient is at least one of the following (e1)-(e4):

[0047] (e1) The methylated CD155 protein according to claim 1;

[0048] (e2) The biomaterial according to claim 3;

[0049] (e3) PRMT6 activator;

[0050] (e4) JMJD6 inhibitors, including compound SKLB325.

[0051] In some preferred embodiments, the active ingredient is a methylated CD155 protein.

[0052] In some preferred embodiments, the active ingredient is a PRMT6 activator.

[0053] In some preferred embodiments, the active ingredient is a JMJD6 inhibitor. More preferably, the JMJD6 inhibitor is SKLB325.

[0054] In this invention, the terms "drug" and "pharmaceutical composition" are used interchangeably. "Drug" or "pharmaceutical composition" refers to a formulation commonly used in the art for delivering bioactive compounds to a medium in mammals (e.g., humans). The purpose of a pharmaceutical composition is to facilitate administration to an organism, thereby promoting the absorption of the active ingredient and the exertion of its biological activity. The term "pharmaceutical" as used herein refers to a substance (such as a pharmaceutical excipient) that does not affect the biological activity or properties of the compounds of this invention and is relatively non-toxic, meaning that the substance can be administered to an individual without causing adverse biological reactions or interacting adversely with any component contained in the composition.

[0055] In this invention, the term "prevention" includes reducing the likelihood of a patient developing or worsening a disease or symptom.

[0056] The term "treatment" and other similar synonyms used in this invention include the following meanings:

[0057] (i) To prevent the occurrence of disease or condition in mammals, especially when such mammals are susceptible to the disease or condition but have not yet been diagnosed with it;

[0058] (ii) To suppress a disease or symptom, that is, to curb its development;

[0059] (iii) To alleviate a disease or symptom, that is, to make the condition of the disease or symptom subside;

[0060] (iv) To alleviate the symptoms caused by the disease or condition.

[0061] In this invention, the term "effective amount" or "therapeutic effective amount" refers to an amount that is effective in producing a preventive or therapeutic effect in humans and / or other animals and is acceptable to humans and / or other animals. The result may be a reduction and / or relief of signs, symptoms, or causes of disease, or any other desired change in a biological system. For example, a "therapeutic effective amount" is the amount of a composition comprising the compounds disclosed herein required to provide significant symptom relief in a clinical setting. Effective amounts suitable for any individual case can be determined using techniques such as dose escalation testing.

[0062] The beneficial effects of the present invention include at least the following:

[0063] This invention discloses for the first time the CD155 protein with arginine methylation at position 109, and reveals a novel mechanism by which epigenetic modification (arginine methylation) directly regulates the function of the immune checkpoint molecule (CD155). This discovery of immune checkpoint regulation through "non-histone methylation" is highly innovative and pioneering in the field. It transcends simple expression-level regulation, delving into the fine-grained regulation of protein function, demonstrating scientific depth and originality.

[0064] The mechanism is clearly explained: This invention not only discloses and verifies for the first time that CD155 methylation can affect the binding with TIGIT, but also systematically identifies the key “writer” (PRMT6) and “erase” (JMJD6), forming a complete molecular loop. This integrity in pathway and mechanism is the core advantage.

[0065] Potential Novel Targets: This invention also proposes for the first time novel, druggable targets (JMJD6, PRMT6). JMJD6 inhibitors (such as SKLB325) or PRMT6 agonists targeting these enzymes could provide a novel TNBC immunotherapy strategy with a different mode of action than existing antibody drugs (anti-TIGIT, anti-PD-1), offering new hope for patients who have developed resistance to existing antibody drugs.

[0066] Clear translational potential: The research in this invention has preliminarily verified the efficacy of the JMJD6 inhibitor SKLB325. This makes the translational pathway of this mechanism very clear, with a well-defined target, enhancing TNBC immunotherapy.

[0067] Other features and advantages of the present invention will be described in detail in the following detailed description section. Attached Figure Description

[0068] Figure 1 The graph shows the results of CD155 R109 methylation-restricted binding of CD155 to TIGIT.

[0069] Figure 2 for Figure 1 An enlarged view of Figure B in the image.

[0070] Figure 3 The CD155 R109 methylation recovery CD8 was shown. + Figure showing the results of T cell function and inhibition of TNBC progression.

[0071] Figure 4 The graph shows the results of PRMT6 catalyzing the methylation of CD155 R109 in TNBC.

[0072] Figure 5 The graph shows the results of PRMT6 regulating the binding of CD155 and TIGIT and its effect on anti-tumor immune response.

[0073] Figure 6 The graph shows the results of JMJD6 regulating the binding of CD155 and TIGIT and the anti-tumor immune response.

[0074] Figure 7 The figure shows the preliminary results of the JMJD6 inhibitor SKLB325 in regulating CD155 R109 methylation. Detailed Implementation

[0075] To make the objectives, technical solutions, and beneficial effects of this invention clearer, the invention will be further described in detail below with reference to specific embodiments. It should be understood that the specific embodiments described in the following description are merely illustrative examples of specific implementations of this invention and are intended to explain the invention, but do not constitute a limitation thereof.

[0076] The endpoints and any values ​​of the ranges disclosed herein are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of the various ranges, the endpoint values ​​of the various ranges and individual point values, and individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed herein. In this invention, when a specific numerical value is mentioned, it means that the value can vary within ±5%. In this invention, unless otherwise stated, terms such as "multiple / a plurality of" mean two / a kind or more. The terms "containing," "comprising," or "including" can be open-ended, semi-closed, or closed.

[0077] The present invention will be described below with reference to specific embodiments. It should be noted that these embodiments are merely illustrative and should not be construed as limiting the invention. It should be noted that if specific conditions are not specified in the embodiments, the techniques or conditions described in the literature in the art or the product instructions should be followed. If the manufacturers of the reagents or instruments used are not specified, they are all commercially available conventional products. Unless otherwise specified, the cloning sequences and expression vectors involved in the following embodiments were obtained from Guangzhou Hanyi Biotechnology Co., Ltd.

[0078] Example 1: CD155 R109 methylation restricts CD155 binding to TIGIT

[0079] Using Dznep to inhibit cellular methylation levels, Co-IP experiments revealed that the binding of CD155 to TIGIT was significantly increased in the Dznep-treated group (e.g., ...). Figure 1 (As shown in Figure A). Specifically, the Co-IP experiment used MDA-MB-231 breast cancer cells, treated with 5 μmol / L Dznep for 48 hours, with cells treated with an equal volume of DMSO as a control; after collecting cell lysates, immunoprecipitation was performed using anti-CD155 antibody, and the precipitated complex was separated by SDS-PAGE and detected by Western blotting using anti-TIGIT antibody, with the amount of CD155 recovered in the immunoprecipitation system detected by anti-CD155 antibody as an internal reference.

[0080] Furthermore, using IP-MS, three methylation sites on the CD155 molecule were identified: R109, R114, and R133 (e.g., ...). Figure 1 Figure B in the middle Figure 2(As shown). The IP-MS method specifically involves: immunoprecipitation of cell lysates from the Dznep-treated group and the control group using an anti-pan-arginine methylation antibody to enrich methylated proteins; separation of the precipitate by SDS-PAGE; excision of gel bands corresponding to the molecular weight region of CD155; intragel digestion with trypsin; and analysis of the obtained peptides by LC-MS / MS mass spectrometry. Database searches identified arginine methylation sites on the CD155 protein, resulting in the selection of three arginine methylation sites: R109, R114, and R133. Molecular cloning techniques were used to mutate the R109, R114, and R133 sites of CD155 to lysine, and these mutants were expressed in HEK-293T cells. Co-IP experiments showed that the mutation at the R109 site significantly enhanced the binding of CD155 to TIGIT (e.g., ...). Figure 1 (As shown in Figure C). The molecular cloning technique specifically includes: using full-length human CD155 cDNA as a template, using site-directed mutagenesis PCR to mutate the arginine codon CGG at sites R109, R114, and R133 to the lysine codon AAG, respectively, to construct CD155. R109K CD155 R114K and CD155 R133K Three single-point mutants were cloned into the pcDNA3.1 eukaryotic expression vector (Guangzhou Hanyi Biotechnology Co., Ltd.) carrying the Flag tag after sequencing verification. The mutant plasmids and wild-type CD155 plasmids were transfected into HEK-293T cells. The lysate was collected 48 hours after transfection and immunoprecipitated with anti-Flag antibody. The co-precipitated TIGIT was detected with anti-TIGIT antibody, and the protein expression level of CD155 of each mutant was detected with anti-Flag antibody. The binding strength between each mutant and TIGIT was compared.

[0081] The study further conducted Co-IP experiments, using anti-arginine methylation antibodies to detect CD155WT and CD155 R109K The results showed that the R109K mutation significantly inhibited CD155 methylation (e.g., arginine methylation modification). Figure 1 As shown in Figure D). Specifically, CD155 wild-type and CD155 R109K The mutant plasmid was transfected into HEK-293T cells. Lysis was collected 48 hours after transfection, and CD155 protein was enriched by immunoprecipitation using anti-Flag antibody. The precipitate was separated by SDS-PAGE, and Western blot was performed using anti-urine methylation antibody and anti-Flag antibody, respectively. The anti-Flag signal was used as a protein loading control. The inhibitory effect of R109K mutation on CD155 methylation level was determined by comparing the intensity of arginine methylation signal under the same amount of CD155 protein.

[0082] Furthermore, Co-IP experiments performed in MDA-MB-231 cells compared the effects of wild-type CD155 and R109K mutant CD155 on TIGIT binding. Results of IP using anti-CD155 antibody showed that CD155... R109K In mutant cells, the binding of CD155 and TIGIT is stronger than that in CD155 wild-type cells (e.g., Figure 1 (As shown in Figure E). The Co-IP experiment performed in MDA-MB-231 cells specifically involved constructing wild-type and CD155 cells carrying the Flag tag. R109K A lentiviral expression vector of the mutant (Guangzhou Hanyi Biotechnology Co., Ltd.) was used to infect MDA-MB-231 cells, followed by puromycin selection to establish cell lines stably expressing wild-type or R109K mutant CD155. Lysates from both stable cell lines were collected and immunoprecipitated using anti-CD155 antibody. The precipitated complexes were separated by SDS-PAGE, and Western blotting was performed using anti-TIGIT and anti-CD155 antibodies, respectively. The anti-CD155 signal was used as an internal reference for immunoprecipitation to compare the co-precipitation amount of TIGIT in the two cell lines under the same CD155 precipitation conditions. Further studies used receptor-ligand binding assays and immunofluorescence detection to identify CD155. R109K The mutant binds to TIGIT more strongly than the CD155 wild type (e.g., Figure 1 (As shown in Figure F). The receptor-ligand binding assay was performed using immunofluorescence. Specifically, HEK-293T cells were transfected with CD155 wild-type and R109K mutant plasmids and seeded in confocal culture dishes. After 48 hours of transfection, recombinant human TIGIT-Fc fusion protein was added and incubated to simulate the receptor-ligand binding of TIGIT to CD155. Subsequently, the bound TIGIT-Fc was detected with anti-human Fc-Alexa Fluor 488 secondary antibody, and the expression and localization of CD155 were detected with anti-Flag-Alexa Fluor 594 antibody. After DAPI staining of the nuclei, images were acquired using a confocal microscope, and the fluorescence intensity of TIGIT-Fc in the CD155-positive region was quantitatively analyzed to compare the difference in the binding ability of TIGIT to CD155 between wild-type and R109K mutant cells.

[0083] Example 2 CD155 R109 methylation recovery CD8 + T cell function, inhibiting TNBC progression

[0084] To investigate whether CD155 R109 methylation affects its immunosuppressive effect on TNBC cells, this invention first constructed a CD155... R109KMutant TNBC cell lines. Specifically, CD155 carrying the Flag tag. R109K MDA-MB-231 triple-negative breast cancer cells were infected with the mutant lentiviral expression vector (pLVX-puro) and selected with 2 μg / mL puromycin for 2 weeks to establish stable expression of CD155. R109K The mutant TNBC cell line was used as a wild-type control, while the same cell line was infected with a lentiviral vector carrying the CD155 wild-type sequence, and cells infected with an empty vector were used as a negative control. The expression level of CD155 protein in the selected stable cell lines was detected by Western blot to verify the overexpression effect.

[0085] Subsequently, the inventors used in vitro constructed TNBC cells with CD8 + T cell co-culture system, CD8 + The immune killing ability of T cells against TNBC cells. The co-culture system specifically involves: using magnetic bead sorting (Miltenyi Biotec, CD8) to separate peripheral blood mononuclear cells from healthy individuals. + CD8 was isolated using the T Cell Isolation Kit. + T cells, activated for 48 hours by anti-CD3 / CD28 antibody-conjugated magnetic beads, will release CD8... + T cells were co-cultured with the TNBC stable cell line constructed above at an effector-target ratio of 10:1 for 24 hours. The co-culture system used RPMI-1640 complete medium containing 10% fetal bovine serum and 100 U / mL IL-2 to maintain T cell activity.

[0086] Flow cytometry results showed that CD155 R109K Mutated tumor cells have a lower apoptosis rate (e.g.) Figure 3 (As shown in Figures A and B), indicating that in CD8 + Under T cell-mediated immune pressure, CD155 R109K Mutant cells are more effectively resistant to clearance by the immune system. The flow cytometry assay specifically involves: collecting co-cultured TNBC cells, staining them with an Annexin V-FITC / PI apoptosis detection kit, and detecting them using a flow cytometer (FACSCalibur, BD). Annexin V single-positive and Annexin V / PI double-positive cells are counted as apoptotic cells. The CD155 level is compared with that of the CD155 wild-type TNBC cell group. R109K The apoptosis rate of tumor cells in the mutant group was measured, and CD8 cells were excluded using an FSC / SSC light scattering gating strategy. + T cells can interfere with test results; if necessary, CD45 antibody labeling can be used to distinguish T cells from tumor cells.

[0087] Further clonogenic experiments (such as) Figure 3 Figures C and D in the figure further confirm this result, indicating that CD155 R109K Mutant TNBC cells interact with CD8 + The colony-forming ability of T cells co-cultured significantly increased, supporting CD155. R109K The conclusion was that mutations enhance tumor cell immune escape. The clonogenic assay was performed as follows: After co-culturing TNBC cells for 24 hours, the cells were digested with trypsin and counted. 500 viable cells were re-seeded into 6-well plates and incubated at 37°C with 5% CO2 for 10-14 days, with the culture medium replaced every 3 days. After incubation, the culture medium was discarded, the cells were washed twice with PBS, fixed with 4% paraformaldehyde for 15 minutes, stained with 0.1% crystal violet for 20 minutes, washed, dried, and photographed. ImageJ software was used to count clones containing more than 50 cells. With the clonogenic rate of the wild-type CD155 group as 100%, the relative clonogenic rates of each group were calculated, and the CD155 clonogenic rate was compared. R109K Mutant group vs. wild-type group at CD8 + Differences in clonogenic capacity under T cell co-culture pressure.

[0088] Example 3: PRMT6 catalyzes CD155 R109 methylation in TNBC

[0089] To identify PRMTs that catalyze arginine methylation of CD155, this invention performed IP-MS analysis on cell samples. The results showed that PRMT6 was the only PRMT that binds to CD155. The IP-MS analysis specifically involved: collecting MDA-MB-231 cell lysates, performing immunoprecipitation with an anti-CD155 antibody to enrich CD155 and its interacting proteins, separating the precipitate by SDS-PAGE, and then performing intragel digestion. The resulting peptides were analyzed by LC-MS / MS mass spectrometry. The mass spectrometry data were compared with the human protein database to identify members of the arginine methyltransferase (PRMT) family that co-precipitate with CD155. A negative control group using isotype control IgG was also set up to exclude interference from non-specific binding. Finally, PRMTs that specifically bind to CD155 were screened from nine family members, from PRMT1 to PRMT9.

[0090] Through Co-IP experiments, the inventors discovered an interaction between PRMT6 and CD155 in the MDA-MB-231 cell line (e.g., Figure 4(As shown in Figure A). Specifically, MDA-MB-231 cell lysates were collected, and an equal amount of total protein (500 μg) was added to either anti-PRMT6 antibody or anti-CD155 antibody for immunoprecipitation, with isotype IgG as a negative control. After separation of the precipitated complex by SDS-PAGE, the co-precipitation of CD155 was detected using anti-CD155 antibody, and the recovery of PRMT6 in the immunoprecipitation system was detected using anti-PRMT6 antibody as a positive control. For reverse IP verification, precipitation was performed using anti-PRMT6 antibody and detection was performed using anti-CD155 antibody, thus verifying the endogenous interaction between PRMT6 and CD155 in MDA-MB-231 cells.

[0091] To further verify this result, the inventors expressed Flag-PRMT6 and HA-CD155 in HEK-293T cells, and similarly found an interaction between PRMT6 and CD155 (e.g., ...). Figure 4 (As shown in Figure B). Specifically, HEK-293T cells were co-transfected with the PRMT6 expression vector carrying the Flag tag (pcDNA3.1-Flag-PRMT6) and the CD155 expression vector carrying the HA tag (pcDNA3.1-HA-CD155), with empty vector co-transfected cells serving as a negative control. Cell lysates were collected 48 hours after transfection, and immunoprecipitation was performed using anti-Flag antibody (to precipitate PRMT6) and anti-HA antibody (to precipitate CD155), respectively. The amount of CD155 co-precipitated was detected by anti-HA antibody, and the amount of PRMT6 co-precipitated was detected by anti-Flag antibody. The interaction between exogenous PRMT6 and CD155 in HEK-293T cells was verified by both forward and reverse immunoprecipitation.

[0092] Furthermore, through GST pull-down experiments, the inventors observed that GST-PRMT6 can effectively bind to His-CD155, indicating that the direct interaction between PRMT6 and CD155 does not depend on other factors (such as... Figure 4(As shown in Figure C). The GST pull-down experiment specifically involved: transforming the GST-PRMT6 fusion protein and the empty GST vector protein into E. coli BL21(DE3), inducing expression with isopropyl-β-D-thiogalactoside (IPTG), and then purifying with glutathione agarose beads to obtain GST-PRMT6 and GST control proteins; simultaneously, transforming the His-CD155 recombinant protein into E. coli and purifying it with a nickel column. Equal amounts of GST-PRMT6 or GST control protein (5 μg each) and His-CD155 recombinant protein (5 μg) were co-incubated in binding buffer (containing 50 mmol / L Tris-HCl pH 7.5, 150 mmol / L NaCl, 0.1% NP-40, and 1 mmol / L LTT) at 4°C for 2 hours by rotation. Glutathione agarose beads were added and incubation continued for 1 hour. After washing three times, the binding products were separated by SDS-PAGE and detected by Western blotting with anti-GST and anti-His antibodies to verify whether GST-PRMT6 directly captures His-CD155, thus demonstrating that the direct interaction between the two does not depend on the mediation of other mammalian cytokines.

[0093] Further research constructed a PRMT6 knockdown MDA-MB-231 cell line. In vitro assays using anti-CD155 antibody showed a significant reduction in CD155 binding to PRMT6 and a significant decrease in CD155 arginine methylation levels (e.g., ...). Figure 4(As shown in Figure D). The construction of the PRMT6 knockdown cell line is as follows: shRNA sequences targeting the PRMT6 gene are designed. The forward sequence of the shRNA is shown in SEQ ID NO 4: 5'-CGGUGCAAGUGGAGCAAGA-3', and the reverse sequence of the shRNA is shown in SEQ ID NO 5: 5'-UCUUGCUCCACUUGCACCG-3'. The shRNA is cloned into the lentiviral vector pLKO.1, packaged into lentivirus, and then used to infect MDA-MB-231 cells. Lentiviral virus carrying non-targeting control shRNA is used as a negative control. After screening with puromycin, the knockdown efficiency is verified by detecting the PRMT6 protein expression level by Western blot (knockdown efficiency ≥70% is considered qualified). Cell lysates from the PRMT6 knockdown group and the control group were collected, and equal amounts of total protein (500 μg) were taken. Immunoprecipitation was performed using anti-CD155 antibody. After separation by SDS-PAGE, the co-precipitated PRMT6 was detected by anti-PRMT6 antibody, the arginine methylation modification level of CD155 was detected by anti-ubiquitin methylation antibody, and the recovery of CD155 in the immunoprecipitation system was detected by anti-CD155 antibody as internal controls. The changes in the amount of PRMT6 bound by CD155 and its methylation level after PRMT6 knockdown were compared.

[0094] Furthermore, in in vitro methylation experiments, the inventors observed that PRMT6 could add a methyl group at the R109 site of CD155 by transfecting Flag-CD155 (wild-type or R109K mutant) with the HA-PRMT6 expression vector. In particular, the R109K mutant CD155 showed a significant decrease in methylation levels, indicating that methylation at the R109 site is crucial for the function of PRMT6 (e.g., Figure 4(As shown in Figure E). The in vitro methylation experiment specifically involves: using wild-type Flag-CD155 or Flag-CD155... The R109K mutant plasmid was co-transfected with the HA-PRMT6 expression vector into HEK-293T cells. Cells transfected solely with Flag-CD155 (without PRMT6 co-transfection) served as a methylation background control. Forty-eight hours after transfection, cell lysates were collected, and CD155 protein was enriched by immunoprecipitation using an anti-Flag antibody. The precipitate was separated by SDS-PAGE, and the methylation signal of CD155 was detected using an anti-ubiquitin methylation antibody. The amount of recovered CD155 protein was measured using an anti-Flag antibody as an internal reference. Simultaneously, the expression level of PRMT6 was detected using an anti-HA antibody. The methylation signal intensity of wild-type CD155 and R109K mutant CD155 under the same PRMT6 expression conditions was compared. If the methylation signal of the R109K mutant group was significantly lower than that of the wild-type group, it indicated that PRMT6 primarily catalyzes the methylation modification of arginine at position 109 of CD155, and that this site is a key site for PRMT6 action.

[0095] Example 4: PRMT6 regulates the binding of CD155 and TIGIT and its anti-tumor immune response.

[0096] To investigate the role of PRMT6 in CD155-TIGIT binding and immune response regulation, this invention first analyzed the role of PRMT6 in the interaction between CD155 and TIGIT using a Co-IP assay. The results showed that in TNBC cells, PRMT6 knockdown significantly enhanced the binding between CD155 and TIGIT (e.g., Figure 5 (As shown in Figure A). Specifically, the lysates of the constructed PRMT6 knockdown (sh-PRMT6) MDA-MB-231 cell line and the control (sh-NC) cell line were collected, and equal amounts of total protein (500 μg) were taken for immunoprecipitation using anti-CD155 antibody, with isotype IgG as a negative control. After separation of the precipitated complex by SDS-PAGE, the co-precipitated TIGIT was detected by anti-TIGIT antibody, the recovery of CD155 in the immunoprecipitation system was detected by anti-CD155 antibody as an internal reference, and the knockdown effect of PRMT6 was verified by anti-PRMT6 antibody. The co-precipitated amount of TIGIT in the CD155 immunoprecipitate in the PRMT6 knockdown group and the control group were compared. If the co-precipitated amount of TIGIT increased significantly after PRMT6 knockdown, it indicates that PRMT6-mediated CD155 methylation negatively regulates the binding of CD155 and TIGIT.

[0097] To further verify the role of PRMT6 in tumor immune escape, this invention constructed a tumor model in mice by subcutaneous inoculation with 4T1 cells, and compared the sh-NC control group with the sh-PRMT6 experimental group. The experimental results showed that the tumor volume in the sh-PRMT6 group mice was significantly increased (e.g., ...). Figure 5 (As shown in Figure B). The animal model was constructed as follows: 4T1 mouse triple-negative breast cancer cells stably expressing sh-PRMT6 and sh-NC controls (this cell line is a mouse TNBC cell line, corresponding to the aforementioned human MDA-MB-231 cells) were collected, resuspended in PBS, and adjusted to a concentration of 1×10⁻⁶. 7 100 μL of cell suspension (containing 1×10⁶ cells / mL) was subcutaneously injected into the right back of 6-8 week old female BALB / c mice (n=6-8 per group). 6 (1 cell); starting from day 7 after inoculation, the long and short diameters of the tumor are measured every 2 days using calipers, according to the formula V = 1 / 2 × long diameter × short diameter. 2 Tumor volume was calculated, and tumor growth curves were plotted up to day 21 post-inoculation. The difference in tumor volume between the sh-PRMT6 group and the sh-NC control group was compared. At the same time, the weight changes and general condition of mice in each group were recorded.

[0098] To further investigate the effect of PRMT6 on immune responses, this invention employed immunofluorescence staining to detect immune cell infiltration in tumor tissues. Results showed that CD8+ in the sh-PRMT6 group of tumor tissues... + T cell infiltration was significantly reduced (e.g.) Figure 5 (As shown in Figure C). The immunofluorescence staining process was as follows: Mice were sacrificed on day 21 after inoculation, tumor tissue was harvested, fixed with 4% paraformaldehyde for 24 hours, dehydrated with 20% and 30% sucrose solutions, embedded in OCT, and then frozen sections were prepared with a thickness of 5 μm. The sections were washed with PBS, permeabilized with 0.1% Triton X-100, blocked with 5% normal goat serum, and incubated overnight at 4°C with anti-CD8α primary antibody (Cell Signaling, 98941, 1:200 dilution). After washing, the sections were incubated at room temperature for 1 hour with Alexa Fluor594-labeled fluorescent secondary antibody, counterstained with DAPI nuclei, mounted, and observed under a confocal microscope. Five high-power fields (200×) were randomly selected from each section, and the number of CD8-positive cells per unit area was calculated using ImageJ software. The CD8 concentration in the tumor tissue of the sh-PRMT6 group and the sh-NC control group was compared. + T cell infiltration density.

[0099] Further analysis using flow cytometry (e.g.) Figure 5 As shown in Figures D and E), the inventors observed CD8 in tumors of the sh-PRMT6 group.+ The proportion of T cells was significantly reduced, and at the same time, these CD8 cells... + The cytotoxic activity of T cells (Granzyme B positive) was also significantly decreased. The flow cytometry analysis specifically involved: mincing the excised tumor tissue, digesting it with collagenase IV (1 mg / mL) and DNase I (100 μg / mL) at 37°C for 30 minutes, and preparing a single-cell suspension by filtration through a 70 μm cell sieve; after cell counting, 1×10⁻⁶ cells were collected. 6 Cells were stained using a zombie aqua stain to remove dead cells, followed by surface staining with anti-mouse CD45-FITC, anti-mouse CD3-APC, and anti-mouse CD8-PE-Cy7 antibodies. The cells were incubated at 4°C in the dark for 30 minutes. After washing, fixation, and permeabilization, intracellular staining with anti-mouse Granzyme B-PE antibody was performed to detect CD8+. + T cell cytotoxicity function; data were acquired using a flow cytometer (BD FACSymphony A5) and analyzed using FlowJo software. Live cells were first selected by gate selection using FSC / SSC and live / dead staining, then CD45⁺CD3⁺CD8⁺ cell populations were sequentially delineated, and CD8⁺ cell counts were performed. + The proportion of T cells among CD45⁺ immune cells, and in CD8⁻ + The percentage of Granzyme B-positive cells in T cell subsets was analyzed, and CD8+ cells were compared between the sh-PRMT6 group and the sh-NC control group. + The differences in the proportion of T cells and their Granzyme B expression levels.

[0100] This result indicates that PRMT6 deficiency not only affects CD8 + The recruitment of T cells and the suppression of their function weaken the anti-tumor immune response.

[0101] Example 5: JMJD6 regulates the binding of CD155 and TIGIT and its anti-tumor immune response.

[0102] To identify the enzyme catalyzing the demethylation of arginine in CD155, this invention performed IP-MS analysis on cell samples. The results showed that JMJD6 was the only arginine demethylase that binds to CD155. The IP-MS analysis specifically involved: collecting MDA-MB-231 cell lysates, performing immunoprecipitation with an anti-CD155 antibody to enrich CD155 and its interacting proteins, using isotype IgG as a negative control; separating the precipitate by SDS-PAGE followed by intragel digestion; analyzing the obtained peptides by LC-MS / MS mass spectrometry; comparing the mass spectrometry data with the human protein database to identify proteins co-precipitated with CD155; and screening known arginine demethylase family members (including JMJD6, PADI4, etc.) from the identification results, ultimately determining JMJD6 as the arginine demethylase that specifically binds to CD155.

[0103] Through Co-IP experiments, the inventors discovered that JMJD6 and CD155 interact in the MDA-MB-231 cell line (e.g., Figure 6 (As shown in Figure A). Specifically, MDA-MB-231 cell lysates were collected, and an equal amount of total protein (500 μg) was taken. Immunoprecipitation was performed using anti-JMJD6 antibody (Abcam, ab108194) and anti-CD155 antibody, respectively, with isotype IgG as a negative control. After separation of the precipitation complex by SDS-PAGE, the co-precipitation of CD155 was detected by anti-CD155 antibody, and the co-precipitation of JMJD6 was detected by anti-JMJD6 antibody. The endogenous interaction between JMJD6 and CD155 in MDA-MB-231 cells was verified by bidirectional precipitation (anti-JMJD6 IP → anti-CD155 detection) and reverse precipitation (anti-CD155 IP → anti-JMJD6 detection).

[0104] Furthermore, the study further transfected HEK-293T cells with wild-type HA-CD155 and R109K-mutated HA-CD155. In vitro immunoassay (IP) using anti-HA antibodies showed that the R109K mutation significantly inhibited arginine methylation levels and the interaction between CD155 and JMJD6 (e.g., Figure 6(As shown in Figure B). Specifically, the CD155 wild-type expression vector (pcDNA3.1-HA-CD155 WT) carrying the HA tag and the CD155 R109K mutant expression vector (pcDNA3.1-HA-CD155R109K) were transfected into HEK-293T cells, respectively, with empty vector transfected cells as a negative control; 48 hours after transfection, cell lysates were collected, and an equal volume of total protein (500 mg / L) was taken. CD155 protein was enriched by immunoprecipitation using an anti-HA antibody (μg). After separation by SDS-PAGE, the methylation level of CD155 was detected by an anti-ubiquitin methylation antibody, the co-precipitated JMJD6 was detected by an anti-JMJD6 antibody, and the amount of CD155 protein recovered was detected by an anti-HA antibody as an internal reference. The methylation signal intensity and the amount of JMJD6 co-precipitated between wild-type CD155 and R109K mutant CD155 under the same protein recovery conditions were compared to verify whether the R109 site is a key site for JMJD6 recognition and demethylation.

[0105] To investigate the regulatory role of JMJD6 on the CD155 / TIGIT axis, the inventors overexpressed JMJD6 in MDA-MB-231 cells and detected the binding strength of CD155 and TIGIT using a Co-IP assay. The results showed that the TIGIT band co-precipitated with CD155 in the JMJD6 overexpression group was significantly stronger than that in the empty vector control group, while the levels of CD155 and GAPDH showed no significant change (e.g., ...). Figure 6 (As shown in Figure C). The construction of the JMJD6 overexpression cell line and the Co-IP experiment were as follows: MDA-MB-231 cells were transfected with the JMJD6 expression vector (pcDNA3.1-Flag-JMJD6) carrying the Flag tag, and cells transfected with the empty vector (pcDNA3.1) were used as a negative control; 48 hours after transfection, cell lysates were collected, and an equal amount of total protein (500 mg / L) was taken. The TIGIT co-precipitation was performed using anti-CD155 antibody (μg). After separation by SDS-PAGE, the co-precipitated TIGIT was detected by anti-TIGIT antibody, the CD155 recovery was detected by anti-CD155 antibody as an internal reference, the overexpression efficiency of JMJD6 was detected by anti-Flag antibody, and the expression levels of PRMT6 and GAPDH were detected by anti-PRMT6 antibody and anti-GAPDH antibody as specific controls. The difference in TIGIT co-precipitation between the JMJD6 overexpression group and the empty vector control group was compared. If the TIGIT co-precipitation was significantly increased after JMJD6 overexpression, it indicated that JMJD6 enhanced the binding of CD155 and TIGIT through demethylation.

[0106] This suggests that JMJD6 restores the binding ability of CD155 to TIGIT by removing the methylation modification at the CD155 R109 site, thereby enhancing the CD155 / TIGIT axis-mediated immunosuppressive signaling. The study further established CD8... + A co-culture system of T cells and JMJD6-overexpressing MDA-MB-231 cells was used. Tumor cell apoptosis was detected by flow cytometry. Preliminary results showed that CD8+ expression was significantly higher in the JMJD6-overexpressing group. + T cell-mediated tumor cell killing efficiency was lower than that of the wild-type control group (e.g., Figure 6 As shown in Figure D), JMJD6 overexpression can attenuate CD8. + The anti-tumor immune activity of T cells was described in the co-culture system and flow cytometry analysis: CD8+ cells were isolated from peripheral blood mononuclear cells of healthy individuals using magnetic bead sorting. + T cells, activated for 48 hours by anti-CD3 / CD28 antibody-conjugated magnetic beads, will release CD8... + T cells were co-cultured with JMJD6-overexpressing MDA-MB-231 cells or empty vector control cells at an effector-to-target ratio of 10:1 for 24 hours. After co-culture, adherent tumor cells (obtained by mild trypsin digestion) were collected and stained with Annexin V-FITC / PI apoptosis detection kit. Annexin V single-positive and Annexin V / PI double-positive cells were counted as apoptotic cells. The apoptosis rate of tumor cells in each group was detected and calculated by flow cytometry. The apoptosis rate of tumor cells in the JMJD6-overexpressing group was compared with that of the empty vector control group. + The efficiency of T cell-mediated tumor cell killing (i.e., the apoptosis rate reflects the killing efficiency) shows that if the apoptosis rate of tumor cells in the JMJD6 overexpression group is significantly lower than that in the control group, it indicates that JMJD6 overexpression can protect tumor cells from CD8+. + T-cell immune killing.

[0107] Example 6: Preliminary Validation of the Regulatory Role of JMJD6 Inhibitor SKLB325 in CD155 R109 Methylation

[0108] To further validate the therapeutic value of targeting JMJD6 and provide experimental evidence for subsequent in vitro and in vivo intervention studies, the inventors conducted a preliminary exploration using the previously reported small molecule inhibitor SKLB325 for JMJD6. In MDA-MB-231 cells, SKLB325 was treated for 48 hours, and the methylation level at the CD155 R109 site was detected by immunoprecipitation combined with Western blotting. The results showed that in the SKLB325 treatment group, the arginine methylation signal detected after immunoprecipitation using HA antibody was significantly stronger than that in the DMSO control group, while the total CD155 protein level showed no significant change (e.g., ...). Figure 7 As shown in Figure A). Specifically, MDA-MB-231 cells were seeded at an appropriate density in 6 cm culture dishes. When the cell confluence reached 70%–80%, SKLB325 was added to the culture medium to a final concentration of 10 μmol / L (this concentration was determined by referring to the half-maximal inhibitory concentration of SKLB325 against JMJD6 in previously reported literature). Cells with an equal volume of DMSO were used as a solvent control. After 48 hours of treatment, cell lysates were collected, and an equal volume of total protein (500 μg) was taken. Immunoprecipitation was performed using anti-CD155 antibody to enrich CD155 protein, with isotype IgG used as a negative control. The precipitate was separated by SDS-PAGE and transferred to a membrane. Anti-ubiquitin methylation antibody (Cell) was used. Signaling (13222, 1:1000 dilution) was used to detect the arginine methylation level of CD155. The recovery of CD155 in the immunoprecipitation system was measured using an anti-CD155 antibody as an internal reference, and the GAPDH level in the cell lysate supernatant (Input) was measured using an anti-GAPDH antibody to ensure consistent loading. The arginine methylation signal intensity was compared between the SKLB325 treatment group and the DMSO control group at the same CD155 protein recovery level to evaluate the effect of SKLB325 on the restoration of methylation at the CD155 R109 site. This indicates that SKLB325 effectively restored the methylation modification at the CD155 R109 site by inhibiting JMJD6 demethylase activity.

[0109] The effect of SKLB325 on CD155 / TIGIT interaction was further investigated using a Co-IP assay. After 48 hours of treatment with SKLB325 in MDA-MB-231 cells, TIGIT binding was detected using immunoprecipitation with anti-CD155 antibody. The results showed that the TIGIT band co-precipitated with CD155 in the SKLB325-treated group was significantly weaker than that in the DMSO control group, while there was no significant difference in CD155 and GAPDH levels in the input (e.g., ...). Figure 7(As shown in Figure B). The Co-IP experiment was conducted as follows: MDA-MB-231 cells were divided into an SKLB325 treatment group (10 μmol / L) and a DMSO control group. After 48 hours of treatment, cell lysates were collected, and an equal amount of total protein (500 μg) was taken for immunoprecipitation using anti-CD155 antibody, with isotype IgG as a negative control. After separation of the precipitated complex by SDS-PAGE, the co-precipitated TIGIT was detected by anti-TIGIT antibody, and the recovery of CD155 in the immunoprecipitation system was detected by anti-CD155 antibody as an internal reference. At the same time, the cell lysate supernatant (Input) of each group was taken for Western blotting. The expression level of total CD155 protein in cells was detected by anti-CD155 antibody, and the level of GAPDH was detected by anti-GAPDH antibody as a loading control to exclude the effect of SKLB325 treatment on the expression level of total CD155 protein. The difference in the amount of TIGIT co-precipitated in the SKLB325 treatment group and the DMSO control group was compared. This suggests that SKLB325-mediated CD155 R109 methylation reversion weakens the binding ability of CD155 to TIGIT.

[0110] To preliminarily evaluate the immunomodulatory effects of SKLB325, the inventors established a CD8... + A co-culture system of T cells and CD155 R109K mutant MDA-MB-231 cells was used, and SKLB325 was applied. Tumor cell apoptosis was detected by flow cytometry. The results showed that the tumor cell apoptosis rate in the SKLB325-treated group was significantly higher than that in the control group (e.g., ...). Figure 7 (As shown in Figure C), this indicates that SKLB325 can recover CD8. + T cell-mediated immune killing function. The co-culture system and flow cytometry detection specifically involved: taking the aforementioned constructed CD155... R109K Stable mutant MDA-MB-231 cell lines were seeded in 6-well plates. When cell confluence reached 60%–70%, the cells were divided into an SKLB325 treatment group (10 μmol / L) and a DMSO control group, and treated for 48 hours. CD8+ cells were isolated from peripheral blood mononuclear cells of healthy individuals using magnetic bead sorting. + T cells, activated for 48 hours by anti-CD3 / CD28 antibody-conjugated magnetic beads, then pretreated with SKLB325 or DMSO, were used to extract CD155 cells. R109K Mutant MDA-MB-231 cells and activated CD8 + T cells were co-cultured at an effector-to-target ratio of 10:1 for 24 hours, with CD8 not added. +The tumor cell culture group with T cells alone served as a background control for spontaneous apoptosis. After co-culture, tumor cells were collected (obtained by mild trypsin digestion) and stained using the Annexin V-FITC / PI apoptosis detection kit. Annexin V single-positive and Annexin V / PI double-positive cells were counted as apoptotic cells. The apoptosis rate of tumor cells in each group was detected by flow cytometry, with the apoptosis rate of tumor cells in the DMSO control group as a benchmark. The apoptosis rate of CD8+ cells in the SKLB325 treatment group was compared. + The efficiency of T cell-mediated tumor cell killing (i.e., an increased apoptosis rate reflecting the recovery of killing function) was assessed. If the apoptosis rate of tumor cells in the SKLB325 treatment group was significantly higher than that in the DMSO control group, it indicates that SKLB325 enhances CD8+ killing efficiency by inhibiting JMJD6 and restoring CD155 R109 methylation. + T cells' immune killing function against CD155 R109K mutant tumor cells.

[0111] Summarize:

[0112] 1. CD155 / TIGIT induces tumor immune escape in TNBC

[0113] Recent studies have revealed that the CD155 / TIGIT axis plays a crucial role in immune escape in various tumors. CD155, an immune system-related molecule widely present on the surface of tumor cells, can inhibit T cell activity by binding to the TIGIT receptor, thereby promoting tumor immune escape. Furthermore, previous research by the inventors has shown that the CD155 / TIGIT pathway may be one of the important mechanisms for tumor cells to escape immune surveillance in TNBC. By blocking the CD155 / TIGIT axis, the anti-tumor function of T cells can be restored, thereby enhancing the efficacy of immunotherapy (Cell Communication and Signaling, 2024). However, although the immune escape mechanism of the CD155 / TIGIT axis has been preliminarily confirmed in TNBC, how to specifically intervene in CD155 expression to regulate the tumor immune response, especially the mechanism of action in the tumor microenvironment, remains unclear. Existing research has largely focused on blocking this axis through anti-TIGIT antibodies, but strategies for directly regulating CD155 remain relatively weak. Therefore, one of the core objectives of this invention is to explore in depth how to modulate the immune response in TNBC by intervening in CD155 expression and its interaction with TIGIT. By optimizing immunotherapy strategies and enhancing T cell recognition and attack on tumors, it is expected to significantly improve the treatment efficacy of TNBC and provide a theoretical basis for personalized immunotherapy.

[0114] 2. Methylation at the CD155 R109 site restricts CD155 binding to TIGIT.

[0115] In recent years, epigenetic studies have shown that the regulation of gene expression depends not only on gene mutations or chromosomal rearrangements, but also on epigenetic modifications, such as histone and non-histone modifications, which play a crucial role in tumor immune escape. Among these, non-histone methylation affects various cellular functions by altering protein function, interactions, and cellular signaling pathways, and its role in immune regulation is receiving increasing attention. Importantly, previous research by the inventors reported that non-histone methylation plays a significant role in regulating TNBC immune responses and has become a potential target for targeted therapy (Pharmacological Research, 2024). Notably, previous studies found that non-histone methylation of the immune checkpoint PD-L1 inhibits its binding to PD-1, thereby reducing immunosuppression. This finding provides a new perspective on immune escape mechanisms, revealing the crucial role of non-histone methylation in immune checkpoint molecules. However, although CD155 is an important molecule for immune escape, it differs significantly from PD-L1, and whether its expression is also regulated by non-histone methylation remains a pressing issue for further research and resolution.

[0116] This invention first investigated the effect of CD155 methylation level on its binding to TIGIT. The study utilized Dznep to inhibit cellular methylation levels, and through co-immunoprecipitation (Co-IP) experiments, it was found that the binding of CD155 to TIGIT was significantly increased in the Dznep-treated group (e.g., ...). Figure 1 (As shown in Figure A). This result indicates that the methylation state of CD155 may play an important regulatory role in its interaction with TIGIT, further suggesting that methylation modification may be a key factor in regulating the CD155-TIGIT immune escape pathway. To further confirm this hypothesis, the study used immunoprecipitation combined with mass spectrometry (IP-MS) to screen for three methylation sites on the CD155 molecule: R109, R114, and R133 (as shown in Figure A). Figure 1 Figure B in the middle Figure 2 (As shown). Among these three sites, the methylation mutation at the R109 site has the most significant regulatory effect on the binding of CD155 to TIGIT, indicating that methylation at the R109 site plays a crucial role in the immune escape function of CD155 (e.g., Figure 1 (As shown in Figure C). Importantly, the study further detected CD155. WT and CD155 R109K The results showed that the R109K mutation significantly inhibited arginine methylation in CD155 (e.g., ...). Figure 1(As shown in Figure D). Further experiments were conducted in the CD155 R109K mutant TNBC cell line. Co-IP and receptor-ligand binding assays showed that the R109 mutation significantly promoted the binding of CD155 to TIGIT in TNBC cells (as shown in Figure D). Figure 1 (As shown in Figures E and F). These experimental results further support the important role of CD155 R109 methylation in immune escape and provide experimental evidence for subsequent targeted immunotherapy based on CD155 methylation modification. However, how CD155 R109 methylation specifically affects its binding mechanism with TIGIT still needs further investigation. The inventors speculate that this effect may be related to conformational changes in the CD155 molecule, or it may change its binding mode with the TIGIT receptor by altering the charge or affinity of certain amino acid residues on CD155. Further elucidation of this mechanism will contribute to a deeper understanding of the role of CD155 methylation in tumor immune escape and provide more theoretical support for the development of targeted immunotherapy.

[0117] 3. Methylation restoration of CD155 R109 site to CD8 + T cell function, inhibiting TNBC progression

[0118] CD155 inhibits CD8 through its interaction with TIGIT. + T cell immune function promotes tumor immune escape. To investigate whether CD155 R109 methylation affects its immunosuppression of TNBC cells, this invention first constructed a CD155 R109-mutated TNBC cell line. Subsequently, the study used in vitro constructed TNBC cells and CD8+ cells... + T cell co-culture system, analysis of CD4 8+ T cells' immune killing ability against TNBC cells. Flow cytometry results showed that tumor cells with CD155 R109K mutations had a lower apoptosis rate, indicating that CD8+ mutations... + Under T-cell-mediated immune pressure, CD155 R109K mutant cells are more resistant to clearance by the immune system (e.g., Figure 3 (As shown in Figures A and B). Clonogenesis experiments further confirmed this, showing that CD155 R109K mutant TNBC cells interacted with CD8... + The clonogenic ability of T cells co-cultured with T cells is significantly increased (e.g. Figure 3 (As shown in Figures C and D). These results indicate that CD155 R109 methylation restores CD8... + The function of T cells effectively inhibited the progression of TNBC.

[0119] This discovery reveals the crucial role of CD155 R109 methylation in TNBC immune escape, demonstrating that altering the immunosuppressive function of CD155 can effectively enhance the anti-tumor activity of T cells. Therefore, CD155 R109 methylation may serve as a novel mechanism for regulating immune escape, providing a potential target for TNBC immunotherapy. However, the specific mechanisms of CD155 R109 methylation are not yet fully understood and require further investigation.

[0120] 4. PRMT6 catalyzes CD155 R109 methylation in TNBC, inhibiting CD155 / TIGIT-mediated tumor progression.

[0121] Non-histone arginine methylation depends on the catalytic action of protein arginine methyltransferases (PRMTs). PRMTs play an important role in various biological processes by transferring methyl groups to arginine residues of target proteins, thereby regulating protein function and interactions. To identify the PRMTs catalyzing CD155 arginine methylation, this invention performed IP-MS analysis on cell samples. The results showed that PRMT6 was the only PRMT that bound to CD155. Further Co-IP experiments confirmed the interaction between PRMT6 and CD155 in TNBC (e.g., Figure 4 As shown in Figures A and B). Through pull-down experiments, this invention also verified the direct interaction between PRMT6 and CD155 (as shown in Figures A and B). Figure 4 (As shown in Figure C). The inventors believe it is necessary to further investigate whether the interaction between PRMT6 and CD155 mediates arginine methylation of CD155.

[0122] Therefore, previous studies constructed a PRMT6 knockdown TNBC cell line. In vitro IP (IP) experiments using anti-CD155 antibody showed that in PRMT6 knockdown TNBC cells, the arginine methylation level of CD155 was significantly decreased (e.g., ...). Figure 4 (As shown in Figure D). Furthermore, in vitro methylation experiments revealed that CD155 with the R109K mutation (replacing arginine with lysine at the R109 site) exhibited a significantly weaker methylation signal, preliminarily indicating that PRMT6 catalyzes CD155 methylation at the R109 site. This result reveals the crucial role of the R109 site in PRMT6-mediated CD155 methylation. More importantly, the next step is to investigate whether PRMT6-mediated CD155 R109 methylation affects the TNBC immune response regulated by the CD155 / TIGIT axis.

[0123] Further research, using Co-IP experiments, revealed that inhibiting PRMT6 expression in TNBC significantly promoted the binding of CD155 to TIGIT (e.g., Figure 5 (As shown in Figure A). Furthermore, in vivo tumor-bearing experiments showed that inhibiting PRMT6 expression significantly promoted TNBC growth (as shown in Figure A). Figure 5 (As shown in Figure B). More importantly, immunofluorescence experiments on tumor tissue sections revealed a significant increase in CD8 molecule expression in PRMT6 knockdown mouse tumor tissues (e.g., ...). Figure 5 (As shown in Figure C). Flow cytometry analysis showed that decreased PRMT6 expression significantly promoted CD8 activation. + T cells and GzmB+CD8 + T cell infiltration level (e.g.) Figure 5 (As shown in Figures D and E). These results suggest that PRMT6 can promote CD8+ methylation by inducing R109 methylation of CD155. + T cell infiltration and activation effectively inhibit the progression of TNBC.

[0124] 5. The role of JMJD6-mediated demethylation of CD155 at R109 and its targeted inhibition in the immune regulation of TNBC.

[0125] Having established that PRMT6 enhances anti-tumor immunity by catalyzing methylation at the CD155 R109 site and inhibiting the CD155 / TIGIT axis, a key scientific question remains to be further investigated: whether there are corresponding demethylases capable of dynamically reversing this modification and thus finely regulating the function of this immune checkpoint pathway. JMJD6, a member of the Jumonji C domain family, plays an important role in histone and non-histone modifications as an arginine demethylase. Furthermore, studies have shown that JMJD6 is abnormally highly expressed in TNBC and promotes tumor progression. To investigate whether JMJD6 participates in the demethylation regulation of CD155 in TNBC, this invention confirmed through Co-IP experiments that JMJD6 can interact with CD155 in TNBC (e.g., ...). Figure 6 (As shown in Figure A). More importantly, in CD155 R109K In mutant cells, not only is the arginine methylation level of CD155 significantly reduced, but the binding of JMJD6 to CD155 is also significantly weakened (e.g., Figure 6 (As shown in Figure B). This result strongly suggests that the R109 site is not only a methylation target catalyzed by PRMT6, but also likely a site of action for JMJD6 demethylation, and that the function of JMJD6 may depend on the integrity of the CD155 R109 site. To verify whether JMJD6 antagonizes the tumor-suppressive function of PRMT6 by demethylating the CD155 R109 site, the study further found that overexpression of JMJD6 in TNBC cells significantly promoted the binding of CD155 to TIGIT (as shown in Figure B). Figure 6(As shown in Figure C). This phenomenon is related to the effects of inhibiting PRMT6 expression (such as...). Figure 5 As shown in Figure A, the orientation is consistent, functionally confirming that JMJD6 acts as an antagonist of PRMT6. By removing the methylation modification at the R109 site, the inhibitory ability of CD155 on T cells is restored. Subsequent in vitro co-culture experiments further confirmed that TNBC cells overexpressing JMJD6 exhibit CD8+ inhibition. + In the presence of T cells, their clonogenic ability is significantly enhanced (e.g., Figure 6 (As shown in Figure D). This indicates that JMJD6 overexpression attenuates CD8. + The killing power of T cells promotes the immune escape of tumor cells.

[0126] Based on the above findings, the inventors further explored intervention strategies targeting JMJD6. Preliminary experimental results show that SKLB325 treatment can significantly restore CD155 R109 methylation levels in TNBC cells and weaken the binding of CD155 to TIGIT (e.g., ...). Figure 7 (As shown in Figures A and B in CD8). + In a co-culture system of T cells and TNBC cells, SKLB325 treatment can enhance CD8. + T cell-mediated tumor cell killing (e.g.) Figure 7 (As shown in Figure C). These results indicate that targeting JMJD6 inhibition can restore CD8 by maintaining the CD155 R109 methylation state. + The anti-tumor immune function of T cells. As a selective JMJD6 inhibitor, SKLB325 is expected to synergize with anti-TIGIT antibodies to further amplify the immune response in TNBC. This invention preliminarily reveals that PRMT6 and JMJD6, a pair of enzymes with opposite functions, dynamically regulate the activity of the CD155 / TIGIT axis through reversible methylation and demethylation modification of the same R109 site on CD155, thus playing a crucial "brake" and "accelerator" role in the TNBC immune microenvironment. The introduction of SKLB325 not only provides a specific chemical probe for mechanistic research but also offers new pharmacological support and clinical translational prospects for developing epiimmunotherapy strategies targeting JMJD6.

[0127] In summary, the CD155 / TIGIT axis in TNBC-mediated tumor immune escape provides a key entry point for this invention. Previous research has confirmed that CD155... R109 Methylation at the site can restrict its binding to TIGIT, thereby restoring CD8. +T cells' immune surveillance function against TNBC. Further research revealed that PRMT6, a key enzyme catalyzing methylation at the CD155 R109 site, enhances methylation at this site, weakens CD155 / TIGIT interaction, and promotes CD8+ methylation. + T cell-mediated anti-tumor immune responses inhibit the progression of TNBC. Based on this, the inventors further revealed that JMJD6, as a demethylase, antagonizes the methylation effect of PRMT6 by specifically removing methylation at the CD155 R109 site, restoring the inhibitory effect of CD155 on T cells, thereby reshaping the immune escape pattern in the TNBC immune microenvironment. Based on the above research, the inventors concluded the following: (1) Methylation at the CD155 R109 site inhibits the binding of CD155 to TIGIT by causing a spatial conformational change in CD155; (2) PRMT6 inhibits the CD155 / TIGIT axis function and enhances CD8+ by catalyzing methylation at the CD155 R109 site. + (3) Inhibitory therapy targeting JMJD6 can maintain the methylation status of CD155R109 site, weaken CD155 / TIGIT-mediated immunosuppression, and restore CD8 + The immune killing function of T cells.

[0128] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and do not constitute a limitation on the content of the present invention. Within the scope of the technical concept of the present invention, various simple modifications can be made to the technical solutions of the present invention, including combining various technical features in any other suitable manner. These simple modifications and combinations should also be regarded as the content disclosed in the present invention and all fall within the protection scope of the present invention.

Claims

1. A methylated CD155 protein, characterized in that, It has an amino acid sequence as shown in SEQ ID NO:1 or an amino acid sequence with at least 70% sequence identity and does not significantly alter the ability to inhibit the binding of CD155 to TIGIT, wherein the 109th position of the CD155 protein is a methylated arginine.

2. The use of at least one of the following (a1)-(a3) in the development, screening, or preparation of a medicament for the prevention and / or treatment of triple-negative breast cancer: (a1) The methylated CD155 protein according to claim 1 is used as a target; (a2) PRMT6, which catalyzes CD155 protein methylation modification, was used as a target; (a3) JMJD6, which is demethylated from CD155 protein, is used as the target.

3. A biomaterial, characterized in that, Includes at least one of the following (b1)-(b4): (b1) A nucleotide sequence expressing the methylated CD155 protein according to claim 1 or a nucleotide sequence having at least 70% sequence identity with the nucleotide sequence and without significantly altering the ability to inhibit the binding of CD155 to TIGIT. (b2) An expression cassette comprising the nucleotide sequence described in (b1); (b3) A recombinant vector comprising the nucleotide sequence described in (b1) or the expression cassette described in (b2); (b4) A recombinant host cell comprising the nucleotide sequence of (b1) or the expression cassette of (b2) or the recombinant vector of (b3).

4. The use of substances that inhibit the binding of CD155 to TIGIT in the development, screening, or preparation of drugs for the prevention and / or treatment of triple-negative breast cancer, characterized in that, The substance that inhibits the binding of CD155 to TIGIT includes at least one of the following (c1)-(c4): (c1) The methylated CD155 protein according to claim 1; (c2) The biomaterial according to claim 3; (c3) PRMT6 activator; (c4) JMJD6 inhibitor.

5. The use of the gene and / or protein in the methylation and demethylation pathway of the CD155 protein at position 109 as described in claim 1 in the preparation, development, screening, or preparation of a medicament for the prevention and / or treatment of triple-negative breast cancer.

6. The application according to claim 5, characterized in that, The genes and / or proteins in the pathway include at least one of the following (d1)-(d2): (d1) PRMT6 gene or protein; (d2) JMJD6 gene or protein; The PRMT6 gene or protein can promote methylation modification, and the JMJD6 gene or protein can demethylate modification, thereby reversibly methylating and demethylating position 109 of CD155 in the pathway.

7. A pharmaceutical composition for treating triple-negative breast cancer, characterized in that, include Therapeutic effective amounts of active ingredients; and Pharmaceutical carriers or pharmaceutical excipients The active ingredient is at least one of the following (e1)-(e4): (e1) The methylated CD155 protein according to claim 1; (e2) The biomaterial according to claim 3; (e3) PRMT6 activator; (e4) JMJD6 inhibitors, including compound SKLB325.

8. The pharmaceutical composition for treating triple-negative breast cancer according to claim 7, characterized in that, The active ingredient is methylated CD155 protein.

9. The pharmaceutical composition for treating triple-negative breast cancer according to claim 7, characterized in that, The active ingredient is PRMT6 activator.

10. The pharmaceutical composition for treating triple-negative breast cancer according to claim 7, characterized in that, The active ingredient is SKLB325.